BR112022006184A2 - BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTARY GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE - Google Patents

BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTARY GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE

Info

Publication number
BR112022006184A2
BR112022006184A2 BR112022006184A BR112022006184A BR112022006184A2 BR 112022006184 A2 BR112022006184 A2 BR 112022006184A2 BR 112022006184 A BR112022006184 A BR 112022006184A BR 112022006184 A BR112022006184 A BR 112022006184A BR 112022006184 A2 BR112022006184 A2 BR 112022006184A2
Authority
BR
Brazil
Prior art keywords
segmentary
glomerulosclerosis
biomarker
focal
kidney disease
Prior art date
Application number
BR112022006184A
Other languages
Portuguese (pt)
Inventor
Francis Reilly John
Dagon Yossi
Raghu Hari
Yveline Coeffet-Le Gal Marie-Francoise
H Daniels Matthew
Yu Maolin
W Ledeboer Mark
P Harmange Jean-Christophe
H Mundel Peter
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of BR112022006184A2 publication Critical patent/BR112022006184A2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TRATAMENTO BASEADO EM BIOMARCADORES DA GLOMERULOESCLEROSE SEGMENTAR FOCAL E DOENÇA RENAL DIABÉTICA. São descritos compostos com fórmulas estruturais (I)-(XI) e composições farmacêuticas relacionadas. Também são descritos métodos de seleção e tratamento de indivíduos humanos que sofrem de uma doença renal, usando os compostos de fórmulas (I)-(XI), e métodos para determinar a eficácia de terapias com inibidor de TRPC5 usando os mesmos.BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTARY GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE. Compounds having structural formulas (I)-(XI) and related pharmaceutical compositions are described. Also described are methods of selecting and treating human subjects suffering from a renal disease, using the compounds of formulas (I)-(XI), and methods of determining the effectiveness of TRPC5 inhibitor therapies using the same.

BR112022006184A 2019-10-04 2020-10-05 BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTARY GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE BR112022006184A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962910758P 2019-10-04 2019-10-04
US2021067946 2021-04-08

Publications (1)

Publication Number Publication Date
BR112022006184A2 true BR112022006184A2 (en) 2022-06-28

Family

ID=83356143

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006184A BR112022006184A2 (en) 2019-10-04 2020-10-05 BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTARY GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE

Country Status (1)

Country Link
BR (1) BR112022006184A2 (en)

Similar Documents

Publication Publication Date Title
BR112015009948A8 (en) Activin-actrii antagonists, uses thereof for treating bone diseases and other disorders, and method for monitoring the effectiveness of treating or preventing a bone disease and other disorders
EA202190630A1 (en) COMBINED THERAPY METHODS
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
BR112018008746A8 (en) compositions and methods for inhibiting arginase activity
BR112016015449A8 (en) therapeutic inhibitory compounds, pharmaceutical composition comprising them and use thereof
UY38613A (en) PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE OF THE SAME
CY1118377T1 (en) SYK IMIDAZOPYRAZIN INHIBITIONS
EA201790740A1 (en) INDOLKARBOXAMIDE CONNECTIONS
BR112022009938A2 (en) SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED TREATMENT METHODS
ECSP21052184A (en) APOL1 INHIBITORS AND THEIR USE METHODS
BR112022002905A2 (en) COMPOSITIONS AND METHODS TO MODULATE SPLICING AND PROTEIN EXPRESSION
MX2022004049A (en) Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease.
MX2020009991A (en) Antibody-based methods of detecting and treating alzheimer's disease.
Bickham et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial
BR112015020235A2 (en) biologically active fragment of csf-1 protein or a homologue thereof, nucleic acid, fusion protein, isolated nucleic acid, vector, host cell, fusion protein embodiment of the first aspect of the invention, composition, use of a fusion protein , method of treatment for an individual suffering from liver cancer and undergoing surgery, method of treatment for an individual undergoing liver transplant surgery, and, kit
EA202192122A1 (en) COMPOUNDS WITH FERROPTOSE-INDUCING ACTIVITY AND METHODS FOR THEIR APPLICATION
BR112022008365A2 (en) CD73 INHIBITORS
BR112023003423A2 (en) APOL1 INHIBITORS AND METHODS OF THEIR USE
BR112021025645A2 (en) Parp14 target protein degradation for use in therapy
MD3852533T2 (en) Pyridazinones and methods of use thereof
CY1124784T1 (en) CO-CRYSTAL OF ORALLY AVAILABLE PROLYL HYDROXYLASE INHIBITOR HIF
BR112022002579A2 (en) Antibodies against ilt2 and their use
EA202091533A1 (en) METHODS FOR TREATMENT OF DIABETES, HEPATITIS AND / OR INFLAMMATORY LIVER DISEASE
EA201790563A1 (en) APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY
BR112022014633A2 (en) ANTI-INTEGRIN ALFAVBETA8 ANTIBODIES FOR USE IN THE TREATMENT OF KIDNEY DISEASE